Thursday, 30th October International Congress on Neuronal Ceroid Lipofuscinoses 2025

9:00AM - 9:30AM
Thursday, 30th October
9:30AM - 10:50AM
Thursday, 30th October
Chairs: Sam Eaton & Samantha Murray

Elizabeth Berry-Kravis

Treatment of CLN1 with TSHA-118 for AAV-9-Mediated PPT1 Gene Transfer Through an Expanded Access Program

Angela Schulz

LTS-101: An Intracerebroventricular Delivered AAV Gene Therapy Using a Novel Capsid Variant for the Treatment of CLN2 Batten Disease

Ewa A Ziółkowska

Dual delivery of gene therapy via intraventricular and intravenous routes in CLN2 disease

Evan Waldo Kleinboehl

Engineered cell micropharmacies for in vivo production of TPP1 as enzyme replacement therapy in CLN2 Batten disease

10:50AM - 11:15AM
Thursday, 30th October
11:15AM - 12:35PM
Thursday, 30th October
Minyama 4
Chairs: Sam Eaton & Samantha Murray

Jonathan D Cooper

Improving the efficacy of enzyme replacement and gene therapy approaches for CLN2 disease via S1S3 phosphotransferase mediated hyperphosphorylation

Miriam MA Aurilia

ESRRA: a new druggable target to tackle Batten disease

Jill M Weimer

Adenine Base Editors: A Novel Approach to Treat CLN2 Disease

Ewa A Ziółkowska

Investigating the pathophysiological basis of dysphagia in CLN1, CLN2, and CLN3 mouse models and the therapeutic effects of gene therapy

12:35PM - 1:35PM
Thursday, 30th October
1:00PM - 2:00PM
Thursday, 30th October
2:00PM - 3:10PM
Thursday, 30th October
Minyama 4
Chair: Jill Weimer

Llinos Honeybun

From cell phenotypes to candidate therapies: high-content screening in CLN3 disease

Magnar Bjørås

CLN3 patient-derived organoids as preclinical platforms for drug screening and gene therapy testing

Clarissa D Booth

Deep, Untargeted Multi-omics Biomarker Landscape in Large Animal Models of CLN1, -2, -3, -5,and -6 Batten Disease

Joelle T Anderson

CLN2 Batten Disease biomarker profiling reveals cardiovascular-associated metabolic dysfunction

3:10PM - 3:35PM
Thursday, 30th October
3:35PM - 5:00PM
Thursday, 30th October
Minyama 4
Chair: Angela Schulz

Lottie D Morison

Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease

Wendy E Heywood

Urinary Glycerophosphoinositol is a potentially non-invasive clinically applicable biomarker for CLN3 disease

Miriam Nickel

Assessment of cognitive decline in CLN3 using the Vineland Adaptive Behavior Scale and the CLN3 Disease Staging System

An N Dang Do

MRI-derived parenchymal volume as a robust biomarker for CLN3 disease progression at the individual level: a longitudinal assessment

5:40PM - 10:00PM
Thursday, 30th October

Be ready for bus departure at 17:40
Pre-registration for the dinner is essential